D espite the federal Schedule I status of cannabis (defined as no currently accepted medical use and high potential for abuse), 28 states and Washington, DC, have enacted medical cannabis laws. 1 An additional 16 states have enacted cannabidiol (CBD)-specific laws. Given that the majority of the United States has laws that involve the cannabis plant or one component of the plant (ie, CBD), it is important for pharmacists and other health care providers to consider the implications of cannabis use for hospital policies and operations.
Hospitals potentially carry enormous risk for allowing cannabis use by patients because cannabis is illegal under federal law. Because they are accredited through the Center for Medicare & Medicaid Services, hospitals could be found to be in violation, lose federal funding, and face penalties. 2 Clinicians are also prohibited from prescribing or providing the drug in a hospital because it is not approved by the US Food and Drug Administration (FDA). Yet, hospitals in more states are asked to create cannabis policies as voters decriminalize cannabis for medical use. There is no recognized supplier of medicinal cannabis, so hospitals are often asked to allow patients to bring in their own supply for their own use. Hospitals are then referred to The Joint Commission Standard MM.03.01.05 policy that states: "The hospital safely controls medications brought into the hospital by patients, their families, or licensed independent practitioners." 3 This standard includes the following elements of performance:
• The hospital defines when medications brought into the hospital by patients, their families, or licensed independent practitioners can be administered.
• Before use or administration of a medication brought into the hospital by a patient, his or her family, or a licensed independent practitioner, the hospital identifies the medication and visually evaluates the medication's integrity. • The hospital informs the prescriber and patient if the medication brought into the hospital by patients, their families, or licensed independent practitioners is not permitted.
Some hospitals have considered cannabis policies that could adequately address this standard, but several questions remain. For example, how is the product identified, how does the institution verify its integrity, and how is a federally illegal drug "permitted"?
Another potential approach is to enact a cannabis policy that considers infrequent or rare cannabis use in the hospital. The hospital may then choose to access the cannabis product through the FDA's expanded access (compassionate use) program. 4 This program allows access for an individual patient or more widespread use when the disease state is serious and a sponsor is actively developing the product. As an example, this expanded access request may be appropriate for institutions wishing to use cannabidiol products currently in development for pediatric intractable seizure disorders.
One important consideration for cannabis use in hospitals is patient safety. We recognize that many institutions may choose to continue to ban cannabis product use by their patients. We also recognize that hospitals may not be able to verify the integrity of the cannabis products used by patients. However, there is still a question about how appropriate or comprehensive the patient care will be if a patient will be taking a different medication regimen while in the hospital versus their usual environment. Issues related to drug interactions and effective transitions of care arise in this scenario. Clinicians need to assess the impact of these products on the patient's status and make a judgment with the patient on whether or not to continue use.
There have been some statements and policies from leading health care organizations urging lawmakers to allow for high-quality cannabis research and patient care considerations. For example, the American Medical Association (AMA) "believes that effective patient care requires the free and unfettered exchange of information on treatment alternatives and that discussion of these alternatives between physicians and patients should not subject either party to criminal sanctions." 5 The American Pharmacists Association (APhA) addresses the role of the pharmacist in the care of patients using cannabis through a policy report that supports standardization of cannabis, advocates for regulatory changes to facilitate clinical research, encourages health care provider education, advocates that the pharmacist collect and document information in the patient profile, and supports pharmacist participation in furnishing cannabis and its various components when scientific data support the legitimate medical use of the products and delivery mechanisms and federal, state, or territory laws or regulations permit pharmacists to furnish them. 6 In a statement by the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine, "a clear policy to guide decisions on when marijuana use is allowed and how to evaluate for impairment must be widely distributed and carefully explained to all workers." 7(p464) If hospitals decide to develop a policy for cannabis use, it is imperative for them to obtain legal consultation during development and to conduct continual review to ensure compliance with federal, state, and case law. The Washington Health Care Association has released a template for a hospital policy that aligns with the laws enacted in that state. 8 Considerations for the policy include qualifying conditions; appropriate documentation by a licensed health care professional, patient, and designated provider(s); mechanisms for provision of cannabis to the patient; staff involvement in the provision of medical cannabis; and consequences for deviating from the policy or negatively affecting the patient's safety and well-being.
Careful consideration must be given to all factors when discussing hospital policies for medical cannabis use. For states in which medical cannabis laws are enacted, it is important for hospital administrators to educate employees about its medical cannabis policy. Pharmacists have an important role in developing hospital policies as well as providing comprehensive patient care, which may include discussion about medical cannabis use.
